A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages

European Journal of Pharmaceutical Sciences

Volumn 34, Issue 1, 2008, Pages 56-65

  Kaur, Jatinder ^a   Muttil, Pavan ^a   Verma, Rahul Kumar ^a   Kumar, Kaushlendra ^a   Yadav, Awadh Bihari ^a   Sharma, Rolee ^a   Misra, Amit ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Aerosol generation; Dry powder inhalation; Inhalation dosimetry; Pulmonary delivery; Respirable microspheres; Tuberculosis

Indexed keywords

ISONIAZID; RIFABUTIN;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARATUS; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG TISSUE LEVEL; DRY POWDER; FEMALE; FLUIDIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MOUSE; NONHUMAN; NOSE; PARTICULATE MATTER; PRIORITY JOURNAL; TUBE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; INHALATION; INJECTIONS, INTRAVENOUS; MACROPHAGES; MALE; MICE; POWDERS; RESPIRATORY SYSTEM; RIFABUTIN; TOXICITY TESTS;

EID: 42649116409     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.02.008     Document Type: Article

References (31)

1. 14C-rifabutin in rats. Antimicrob. Agents Chemother. 35 (1991) 1391-1396
2. Ben-Jebria A., Eskew M.L., and Edwards D.A. Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles. Aerosol Sci. Technol. 32 (2000) 421-433
3. Brain J., Knudson D., Sorokin S., and Davis M. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 11 (1976) 13-33
4. Calleja I., Blanco-Pŕi{dotless}eto M.J., Ruz N., Renedo M.J., and Dios-Viéitez M.C. High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. J. Chromatogr. A 1031 (2004) 289-294
5. Ellis N., Bi H., Lim C., and Grace J. Hydrodynamics of turbulent fluidized beds of different diameters. Powder Technol. 141 (2004) 124-136
6. Henderson R.F., Hahn F.F., Benson J.M., Barr E.B., Bechtold W.E., Burt D.G., and Dahl A.R. Dosimetry and acute toxicity of inhaled butadiene diepoxide in rats and mice. Toxicol. Sci. 51 (1999) 146-152
7. Ikegami K., Kawashima Y., Takeuchi H., Yamamoto H., Mimura K., Momose D., and Ouchi K. A new agglomerated KSR-592 beta-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. J. Control. Release 88 (2003) 23-33
8. Kawahara Y., Tanonaka K., Daicho T., Nawa M., Oikawa R., Nasa Y., and Takeo S. Preferable anesthetic conditions for echocardiographic determination of murine cardiac function. J. Pharmacol. Sci. 99 (2005) 95-104
9. Kawashima Y., Serigano T., Hino T., Yamamoto H., and Takeuchi H. Surface-modified antiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologically effective dose. Pharm. Res. 15 (1998) 1753-1759
10. Leong K.H. Theoretical principles and devices used to generate aerosols for research. In: Hickey A.J. (Ed). Pharmaceutical Inhalation Aerosol Technology (2004), Marcel Dekker, New York 253-278
11. Lewis R.C., Hatfield N.Z., and Narang P.K. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm. Res. 8 (1991) 1434-1440
12. Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., and Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32 (2007) 140-150
13. Ohmori Y., Onoue S., Endo K., Matsumoto A., Uchida S., and Yamada S. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. Life Sci. 79 (2006) 138-143
14. Oldham M.J., Phalen R.F., Robinson R.J., and Kleinman M.T. Performance of a portable whole-body mouse exposure system. Inhal. Toxicol. 16 (2004) 657-662
15. Pauluhn J. Validation of an improved nose-only exposure system for rodents. J. Appl. Toxicol. 14 (1994) 55-62
16. Pauluhn J. Mosquito coil smoke inhalation toxicity. Part I: Validation of test approach and acute inhalation toxicity. J. Appl. Toxicol. 26 (2006) 269-278
17. Pauluhn J., and Thiel A. A simple approach to validation of directed-flow nose-only inhalation chambers. J. Appl. Toxicol. 27 (2007) 160-167
18. Rao D., and Cederbaum A. A comparative study of the redox-cycling of a quinone (rifamycin s) and a quinonimine (rifabutin) antibiotic by rat liver microsomes. Free Radical Biol. Med. 22 (1997) 439-446
19. Rau J.L. Practical problems with aerosol therapy in COPD. Respir. Care 51 (2006) 158-172
20. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug. Deliv. Rev. 58 (2006) 1030-1060
21. Sakagami M., and Byron P.R. Respirable microspheres for inhalation: The potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin. Pharmacokinet. 44 (2005) 263-277
22. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
23. Sharma R., Muttil P., Yadav A.B., Rath S.K., Bajpai V.K., Mani U., and Misra A. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother. 59 (2007) 499-506
24. Sharma R., Saxena D., Dwivedi A.K., and Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18 (2001) 1405-1410
25. Svensson S., Olin A.C., and Hellgren J. Increased net water loss by oral compared to nasal expiration in healthy subjects. Rhinol. 44 (2006) 74-77
26. Upton R.N., and Doolette D.J. Kinetic aspects of drug disposition in the lungs. Clin. Exp. Pharmacol. Physiol. 26 (1999) 381-391
27. Voss A., and Finlay W.H. Deagglomeration of dry powder pharmaceutical aerosols. Int. J. Pharm. 248 (2002) 39-50
28. 2 particle formulations: impact of surface treatments on particle toxicity. Toxicol. Sci. 88 (2005) 514-524
29. Wildhaber J.H., Waterer G.W., Hall G.L., and Summers Q.A. Reducing electrostatic charge on spacer devices and bronchodilator response. Br. J. Clin. Pharmacol. 50 (2000) 277-280
30. Zijlstra G.S., Brandsma C.A., Harpe M.F., Van Dam G.M., Slebos D.J., Kerstjens H.A., De Boer A.H., and Frijlink H.W. Dry powder inhalation of hemin to induce heme oxygenase expression in the lung. Eur. J. Pharm. Biopharm (2007)
31. Ziman J.M. Principles of the Theory of Solids (1969), Cambridge University Press, Cambridge, UK pp. 116-123; 179-200